Fish Oil News and Research

RSS

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

A new analysis has found that supplementing the diet with fish oil may prevent muscle and weight loss that commonly occurs in cancer patients who undergo chemotherapy. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that fish oil may help combat cancer-related malnutrition.

28 Feb 2011

Omega-3 fish oils: Natural health solution for the heart

Did you know that over the average life span, a heart beats 2 to 3 billion times? As one of the hardest working muscles pumping oxygen and essential nutrients throughout your body an average of 100,000 times a day, the heart needs a lot of help to stay working fit.

25 Feb 2011

Tips for heart healthiness

Everyone should know the warning signs for a heart attack -- but according to Dr. Isaac Eliaz, effective prevention requires much more than a list of potential symptoms.

23 Feb 2011

Avesthagen completes development of microalgae based vegetarian DHA omega 3 essential fatty acid

Avesthagen Limited announced completion of a landmark project for the development of AvestaDHA(TM) - a vegetarian source of DHA (docohexanoic acid) omega 3 essential fatty acid based on an innovative approach using naturally occurring microalgae.

17 Feb 2011

Diet high in Omega 3 oils benefits at risk Alzheimer's disease patients

Scientists today agree that there are five molecules that are known to affect or cause Alzheimer's disease, which plagues an estimated five million Americans. The potency of these molecules is linked to environmental factors such as diet and lifestyle.

16 Feb 2011

Scientist finds potential positive influence of fish oil omega-3 fatty acids on cardiovascular health

A Michigan Technological University scientist is finding a growing body of evidence suggesting that the omega-3 fatty acids found in fish oil protect against cardiovascular disease.

14 Feb 2011

Five tips to lower cholesterol

An estimated 102 million Americans have cholesterol levels that are considered borderline high-risk. This staggering fact makes lowering cholesterol one of the most imperative things to do to promote overall heart health. Unfortunately, too few people understand the essential steps in reaching this goal.

9 Feb 2011

Nordic Naturals launches one-per-day omega-3 fatty acid gels

Nordic Naturals introduces Daily Omega, a line of three products that offers a simple solution for consumers concerned about what type of product to take on a regular basis to address their need for omega-3 essential fatty acids.

25 Jan 2011

Omega-3 fatty acid may help protect against traumatic brain injury

Animal experiments suggest that taking the omega-3 fatty acid docosahexanoic acid (DHA) might offer a new way of protecting against traumatic brain injury (TBI), reports the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

10 Jan 2011

Omega-3 EPA or combination of EPA and DHA provide clear antidepressant benefits

Researchers at the University of Illinois at Chicago completed a review of previously published research on antidepressant benefits of Omega-3 essential fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The review comprised a meta-analysis of 15 randomized, double-blind, placebo-controlled studies in patients with depression and results were presented at the recent annual meeting of the American College of Neuropsychopharmacology.

16 Dec 2010

Atrium acquires Belgium-based Minami Nutrition

Atrium Innovations Inc., a recognized leading developer, manufacturer and marketer of professionally endorsed, science-based dietary supplements for the health and nutrition industry, today announced the purchase of Belgium-based Minami Nutrition, a niche brand of superior quality scientifically proven Omega-3 products primarily sold in several European countries.

15 Dec 2010

ONC enters exclusive long term strategic agreement with Wilmar

Ocean Nutrition Canada Limited (ONC), the world's largest Omega-3 EPA/DHA solutions provider, and supplier of MEG-3® brand Omega-3 EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) ingredients, is pleased to announce that it has entered into an exclusive long term strategic agreement with Wilmar International Limited (Wilmar), based in Singapore.

14 Dec 2010

UCLA findings could lead to enhanced health supplements, progress on Parkinson's

The discovery by UCLA biochemists of a new method for preventing oxidation in the essential fatty acids of cell membranes could lead to a new class of more effective nutritional supplements and potentially help combat neurodegenerative disorders such as Parkinson's disease and perhaps Alzheimer's.

3 Dec 2010

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Neptune Technologies & Bioressources Inc. subsidiary, Acasti Pharma Inc., reports the completion of its preclinical program designed to compare the lipid management effects of Acasti's drug candidate CaPre versus prescription drug Lovaza.

25 Nov 2010

Warfarin taken along with herbal, dietary supplements may be dangerous

Herbal and dietary supplements are popular. People claim they make their joints feel better, their bones stronger, and their hearts healthier. But a recent study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City shows that many of these people may not realize their favorite supplement, mixed with prescription medications, may be putting their lives in danger, especially if they are taking warfarin - a blood-thinning medication commonly prescribed to patients living with atrial fibrillation to lower their risk of stroke.

17 Nov 2010

High-dose prescription omega-3 does not reduce recurrence of atrial fibrillation

Although some data have suggested that omega-3 fatty acid supplements, such as from fish oil, may improve treatment of atrial fibrillation, a randomized trial with more than 600 patients finds that treatment with high-dose prescription omega-3 did not reduce the recurrence of atrial fibrillation over six months, according to a study that will appear in the December 1 issue of JAMA. The study is being released early online because it will be presented at the American Heart Association's annual meeting.

15 Nov 2010

Dreaded cod liver oil in a variety of flavours

The stomachs of the generation of 50 year olds and above, will be churning at the thought of their parents and grandparents serving up spoonfuls of the much dreaded cod liver oil. As a practice, parents giving their children cod liver oil has all but died, and yet, as a population, we have seen more and more inflammatory conditions effect people's lives, which are due in no small part to the 'modern day diet', which many of us live.

12 Nov 2010

Media has misrepresented facts about Omega-3 DHA Alzheimer's study, says Ocean Nutrition Canada

Several media outlets published articles last week suggesting that Omega-3 fish oil supplements fail to show positive results for Alzheimer's patients. This reporting by media outlets came after the Journal of the American Medical Association (JAMA) published the study "Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial", where researchers reported that "Supplementation with DHA compared with placebo did not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer disease."

11 Nov 2010

DHA protects brain tissue and promotes recovery in acute ischemic stroke

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is a powerful therapeutic agent that can protect brain tissue and promote recovery in an experimental model of acute ischemic stroke, even when treatment is delayed by up to five hours.

9 Nov 2010

CaPre drug candidate effective in managing impaired glucose tolerance

Neptune Technologies & Bioressources Inc. subsidiary Acasti Pharma Inc. reports preclinical results showing that its leading drug candidate CaPre, performed significantly better than the currently marketed drug, Lovaza, at managing impaired glucose tolerance (IGT) a serious pre-diabetic state associated with increased risk of diabetes and heart disease.

4 Nov 2010